✨ Free AI Report
Compugen Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Compugen Ltd.
Company Research

Compugen Ltd.: Business Overview, Financials & Competitive Analysis

Compugen Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage biotech with differentiated AI-powered drug discovery and validating partnerships, offset by minimal near-term revenue and execution risk on late-stage trials. The company's AI/ML-powered computational discovery platform addresses a critical need in oncology drug development. However, revenue of $2.2 million in Q1 2026 declined 4.7% year-over-year, continuing anemic top-line performance.

What is Compugen Ltd.'s industry? Compugen Ltd. (cgen.com) operates in Biotechnology - Oncology Immunotherapy. AskCyborg classifies Compugen Ltd. under Biotechnology - Oncology Immunotherapy in its company registry.

Compugen Ltd is a clinical-stage cancer immunotherapy company. The company is focused on therapeutic discovery and development, utilizing its AI/ML-powered computational discovery capabilities to identify novel drug t...

6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with differentiated AI-powered drug discovery and validating partnerships, offset by minimal near-term...

Read the full analyst-debate transcript →
Industry Biotechnology - Oncology Immunotherapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Compugen Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Compugen Ltd.

AskCyborg analysts argue the bull and bear cases for Compugen Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Compugen Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Compugen Ltd. Overview

Pro stress-test →

Compugen Ltd is a clinical-stage cancer immunotherapy company. The company is focused on therapeutic discovery and development, utilizing its AI/ML-powered computational discovery capabilities to identify novel drug targets and biological pathways.

Strategic Profile

Pro stress-test →

With a market capitalization of approximately $197.94 million, Compugen is actively working on several clinical-stage programs, including COM701, which targets immune checkpoints discovered through computational methods. The company has a solid financial position with a cash runway expected to last into 2029, supported by a non-dilutive transaction in December 2025 providing $65 million upfront and a potential $25 million milestone payment from AstraZeneca royalties.

Competitive Landscape

Pro stress-test →

Compugen competes in immuno-oncology with partnerships including Bristol-Myers Squibb on COM701 combinations and AstraZeneca for bi-specific antibody development. The company differentiates through its computational AI/ML platform for target discovery rather than traditional screening approaches, competing with larger pharma and specialized biotech in oncology immunotherapy.

Industry Context

Compugen Ltd. operates in Biotechnology - Oncology Immunotherapy.

Key facts

Founded: 1993 · Headquarters: Holon, Israel · Revenue: $2.18M (Q1 2026) · Market cap: $197.94M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Compugen Ltd..

  • On June 11, 2026, Compugen announced plans to present its latest progress on the MAIA-ovarian trial at the European Oncology Congress
  • The company has initiated the MAIA-ovarian adaptive platform trial to test COM701 as a maintenance therapy, with active patient enrollment across the United States, Israel, and France
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2026Presented MAIA-ovarian trial progress at European Oncology Congress
  • May 2026Q1 2026 revenue of $2.18M slightly beat analyst estimates despite EPS miss
  • +2 moreTrack every material event for Compugen Ltd. as it happens. Explore monitoring →
Get alerted when Compugen Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

OpdivoPD-1 immune checkpoint inhibitor→KeytrudaPD-1 checkpoint inhibitor for oncology→JemperliPARD1 checkpoint inhibitor→

Compare Compugen Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Compugen Ltd. operates in Biotechnology - Oncology Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Oncology Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Compugen Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Compugen Ltd. and its top competitor on Cyborg Score”
“What did Compugen Ltd. do this quarter?”
“Is Compugen Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Compugen Ltd. do?+
Compugen Ltd is a clinical-stage cancer immunotherapy company. The company is focused on therapeutic discovery and development, utilizing its AI/ML-powered computational discovery capabilities to identify novel drug t...
What is Compugen Ltd.'s Cyborg Score?+
Compugen Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Compugen Ltd.'s main competitors?+
Named competitors include Opdivo, Keytruda, Jemperli. The full competitive landscape is in the AskCyborg report.
How can I get the full Compugen Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Compugen Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Compugen Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.